Related Experiment Video
Updated: Jan 26, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
An update on heart disease risk associated with testosterone boosting medications
G Corona1, G Rastrelli2, F Guaraldi1,3
1a Endocrinology Unit, Medical Department, Azienda-Usl Bologna , Maggiore-Bellaria Hospital , Bologna , Italy.
Introduction:
The cardiovascular (CV) safety of testosterone replacement therapy (TRT) remains a crucial issue in the management of subjects with late-onset hypogonadism. The authors systematically reviewed and discussed the available evidence focusing our analysis on heart-related issues.
Areas Covered:
All the available data from prospective observational studies evaluating the role endogenous T levels on the risk of acute myocardial infarction (AMI) were collected and analyzed. In addition, the impact of TRT on heart-related diseases, as derived from pharmaco-epidemiological studies as well as from randomized placebo-controlled trials (RCTs), was also investigated.
Expert Opinion:
Available evidence indicates that endogenous low T represents a risk factor of AMI incidence and its related mortality. TRT in hypogonadal patients is able to improve angina symptoms in subjects with ischemic heart diseases and exercise ability in patients with heart failure (HF). In addition, when prescribed according to the recommended dosage, TRT does not increase the risk of heart-related events.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Heart Failure V: Medical Management
Testosterone: Functions and Regulation
Rheumatic Heart Disease I: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Rheumatic Heart Disease IV: Nursing Management

